|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The acute and chronic effect of sulfonylurea therapy in type II diabetic patients 显示文摘 | KOLTERMAN OG GRAY RS SHAPIRO G | 1984 | Diabetes1984，33，4： | 1 |
| 2 | Pharmacokinetics,pharmacodynamics,and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | Kolterman OG Kim DD Shen L | | 0，，02： | 1 |
| 3 | The effects of oral fructose,sucrose,and glucose in subjects with reactive hypoglycemia显示文摘 | Crapo PA Scarlett JA Kolterman OG | 1982 | Diabetes Care1982，5，5： | 1 |
| 4 | Longitudinal evaluation of the effects of sultbnylurea therapy in subjects with type II diabetes mellitus显示文摘 | Kolterman OG | 1985 | Am J Med1985，79，3： | 1 |
| 5 | Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | Kolterman OG Kim DD Shen L | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 6 | Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | J Clin Endocrinol Metab2003，88，7： | 1 |
| 7 | Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus 显示文摘 | Kolterman OG Kim DD Shen L | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 8 | Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus 显示文摘 | Kolterman OG Kim DD Shen L | 2005 | Am Health Syst Pharm2005，62，2： | 1 |
| 9 | Synthetic Exendin-4 (AC2993) Signify eantly reduces post-prandial and fasting plasma glucose insubjects with type 2 diabetes显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | Clin Endocrinol Metab2003，88，7： | 1 |
| 10 | Pharmaeoki- netics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus 显示文摘 | Kolterman OG Kim DD Shen L | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 11 | Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes 显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | J Clin Endocrinal Metab2003，88，7： | 1 |
| 12 | Synthetic exendin-4 (AC2993) significantly reduces postprandial and fasting plasma glu- cose in subjects with type 2 diabetes 显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | J Clin Endocrinol Metab2003，88，7： | 1 |
| 13 | Synthetic exendin-4(exeatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | J Clin Endocrinol Metab2003，88，7： | 1 |
| 14 | Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | J Clin Endocrianl Metab2003，88，7： | 1 |
| 15 | Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | KOLTERMAN OG KIM DD SHEN L | 2005 | AmJ Health Syst Pharm2005，62，2： | 1 |
| 16 | Pharmacokinetics pharmacodynamies, and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | KOLTERMAN OG KIM DD SHEN L | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 17 | Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes显示文摘 | Olefsky JM Kolterman OG | 1981 | Am J Med1981，70，1： | 1 |
| 18 | Effect of 6-week course of glucagon-like peptide 1 on glycaemic control,insulin sensitivity,andβ-cell function in type 2 diabetes:a parallel-group study显示文摘 | Zander M Kolterman OG Kolterman OG | 2002 | Lancet2002，359，8： | 1 |
| 19 | Synthetic exenatide-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | J Clin Endocr Metab2003，88，7： | 1 |
| 20 | Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subiects with type 2 diabe- tes显示文摘 | Kolterman OG Buse JB Fineman MS | 2003 | J Clin Endocrinol Metab2003，88，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员